Monoclonal antibody aiming at bordetella pertussis antibody as well as preparation method and application thereof
By developing a monoclonal antibody against Bordetella pertussis, and using flow cytometry and reverse transcription PCR technology to prepare a highly sensitive quality control antibody, the problems of long diagnostic time and inconsistent results in the existing technology for pertussis were solved. This enabled rapid and accurate detection of PT-IgG antibody concentration in serum, which is suitable for in vitro diagnostic kits.
Patent Information
- Application Number
- CN202511848846.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2025-12-09
- Publication Date
- 2026-01-09
AI Technical Summary
Existing diagnostic methods for pertussis are time-consuming, dependent on doctors' experience, and produce inconsistent test results. The incidence rate is rising, especially among infants and adolescents/adults who have not completed their immunization schedules, making it difficult for existing methods to achieve rapid and accurate diagnosis.
We developed a monoclonal antibody against Bordetella pertussis, prepared a highly sensitive quality control antibody by specifically screening for pertussis toxin antibodies, and applied it to an in vitro diagnostic kit for rapid detection of PT-IgG antibody concentration in serum. By combining flow cytometry and reverse transcription PCR technology, the development cycle was shortened to 3 months.
It enables rapid and accurate diagnosis of pertussis, reduces testing time, and improves the reliability and consistency of test results, making it suitable for quantitative detection of clinical samples.